

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended February 29, 2024 and February 28, 2023 (In Canadian Dollars)

#### NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The accompanying condensed interim consolidated financial statements of the Tocvan Ventures Corp. (the "Company") have been prepared by management and approved by the Board of Directors of the Company. The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

April 29, 2024

#### TOCVAN VENTURES CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited, Expressed in Canadian Dollars)

|  | Note            | February 29,<br>2024                | August 31, 2023                       |
|--|-----------------|-------------------------------------|---------------------------------------|
| ASSETS   |                 |                                     |                                       |
| CURRENT  |                 |                                     |                                       |
| Cash   |                 | \$<br>47,376                        | \$<br>20,825                          |
| Receivables  | 5               | 104,638                             | 134,859                               |
| Prepaid expenses   | 6               | 65,486                              | 64,187                                |
| Financial asset  | 4               | 374,662                             | 1,355,240                             |
| TOTAL CURRENT ASSETS   |                 | 592,162                             | 1,575,111                             |
| Exploration and evaluation assets  | 3, 10           | 7,245,440                           | 6,326,145                             |
| TOTAL ASSETS   |                 | \$<br>7,837,602                     | \$<br>7,901,256                       |
| CURRENT<br>Accounts payable and accrued liabilities<br>Due to related parties<br>Debenture payable | 7<br>10<br>4, 9 | \$<br>193,477<br>592,693<br>663,398 | \$<br>366,304<br>519,086<br>1,958,304 |
| Warrants payable   | ч, у<br>4       | 168,111                             | 777,435                               |
| TOTAL CURRENT LIABILITIES  |                 | 1,617,679                           | 3,621,129                             |
| SHAREHOLDERS' EQUITY   |                 |                                     |                                       |
| Share capital  | 8,13            | 11,535,514                          | 9,373,703                             |
| Reserves   | 8               | 2,005,049                           | 1,676,070                             |
| Deficit  |                 | (7,320,640)                         | (6,769,646)                           |
| TOTAL SHAREHOLDERS' EQUITY   |                 | 6,219,923                           | 4,280,127                             |
| TOTAL LIABILITIES AND SHAREHOLDERS'<br>EQUITY  |                 | \$<br>7,837,602                     | \$<br>7,901,256                       |

Nature and continuance of operations (Note 1) Subsequent events (Note 13)

/s/ Brodie A. Sutherland

Director

/s/ Rodrigo Calles Montijo

Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

# TOCVAN VENTURES CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(Unaudited, Expressed in Canadian Dollars)`

|  |      |    | Three mor          | nths | ended              |    | Six montl           | ns e | nded               |
|--|------|----|--------------------|------|--------------------|----|---------------------|------|--------------------|
|  | Note | Fe | bruary 29,<br>2024 | Fe   | bruary 28,<br>2023 | Fe | ebruary 29,<br>2024 | Fe   | bruary 28,<br>2023 |
| EXPENSES   |      |    |                    |      |                    |    |                     |      |                    |
| Advertising and promotion  |      | \$ | 33,349             | \$   | 376,404            | \$ | 87,527              | \$   | 580,936            |
| Audit and accounting   |      |    | 27,061             |      | 46,570             |    | 29,122              |      | 48,126             |
| Consulting   | 10   |    | 115,500            |      | 38,822             |    | 228,000             |      | 66,788             |
| Financing fee  |      |    | _                  |      | _                  |    | -                   |      | 3,675              |
| Legal  |      |    | 9,112              |      | 20,245             |    | 25,933              |      | 32,196             |
| Management fees  | 10   |    | 12,000             |      | 15,000             |    | 24,000              |      | 32,000             |
| Meals and entertainment  |      |    | _                  |      | 1,721              |    | 959                 |      | 11,502             |
| Office and miscellaneous   |      |    | 9,438              |      | 9,650              |    | 23,962              |      | 15,638             |
| Registration and transfer agent fees                                 |      |    | 16,618             |      | 20,669             |    | 31,985              |      | 31,225             |
| Share-based compensation   | 8,10 |    | 24,609             |      | 165,585            |    | 279,244             |      | 481,588            |
| Travel   |      |    | 9,947              |      | 6,236              |    | 13,468              |      | 21,285             |
| Operating expenses   |      |    | (257,634)          |      | (700,902)          |    | (744,200)           | (    | (1,324,959)        |
| Other (loss)/gain  |      |    |                    |      |                    |    |                     |      |                    |
| Foreign exchange loss  |      |    | (9,528)            |      | (129,140)          |    | (12,033)            |      | (136,151)          |
| Interest expense   |      |    | (4,736)            |      | (6,926)            |    | (11,400)            |      | (13,930)           |
| Realized loss on swap settlement                                     |      |    | (311,543)          |      | (158,411)          |    | (533,075)           |      | (317,281)          |
| Unrealized gain/(loss) on financial asset                            |      |    | 279,067            |      | 215,418            |    | 221,331             |      | (47,977)           |
| Unrealized gain on debenture payable                                 |      |    | 145,662            |      | _                  |    | 612,629             |      | 394,103            |
| Realized loss on debenture payable                                   |      |    | (373,320)          |      | _                  |    | (693,570)           |      | -                  |
| Unrealized gain on warrants payable                                  |      |    | 124,574            |      | 189,018            |    | 609,324             |      | 509,464            |
| Total other items  |      |    | (149,824)          |      | 109,959            |    | 193,206             |      | 388,228            |
| Net loss and comprehensive loss for the period                       |      | \$ | (407,458)          | \$   | (590,943)          | \$ | (550,994)           | \$   | (936,731)          |
| Loss per share, basic and diluted                                    |      | \$ | (0.01)             | \$   | (0.02)             | \$ | (0.01)              | \$   | (0.03)             |
| Weighted average number of shares<br>outstanding – basic and diluted |      |    | 42,926,666         |      | 37,609,145         |    | 41,600,975          |      | 37,326,653         |

# TOCVAN VENTURES CORP. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

(Unaudited; Expressed in Canadian dollars)

|  | Share Ca   | apital        |             |               |              |
|--|------------|---------------|-------------|---------------|--------------|
|  | Number of  | •             |             |               |              |
|  | Shares     | Amount        | Reserves    | Deficit       | Total Equity |
| Balance at August 31, 2022               | 36,270,650 | \$ 7,694,247  | \$ 902,334  | \$(5,009,158) | \$3,587,423  |
| Shares issued on exercise of options     | 31,250     | 11,563        | _           | —             | 11.563       |
| Shares issued on exercise of warrants    | 9,600      | 5,760         | _           | —             | 5,760        |
| Shares issued for exploration properties | 1,000,000  | 650,000       | _           | —             | 650,000      |
| Units issued for cash                    | 1,227,353  | 638,224       | _           | _             | 638.224      |
| Units issued for services                | 218,000    | 109,000       | _           | _             | 109.000      |
| Share issuance costs                     | _          | (98,260)      | 26,518      | _             | (71,742)     |
| Share-based compensation                 | —          | _             | 481,588     | _             | 481,588      |
| Loss for the period                      | _          | _             | —           | (936,731)     | (936,731)    |
| Balance at February 28, 2023             | 38,756,853 | \$ 9,010,534  | \$1,410,440 | \$(5,945,889) | \$4,475,085  |
| Balance at August 31, 2023               | 39,985,108 | \$ 9,373,703  | \$1,676,070 | \$(6,769,646) | \$4,280,127  |
| Shares issued on conversion of debenture |            |               |             |               |              |
| payable                                  | 1,683,600  | 1,380,552     | _           | —             | 1,380,552    |
| Shares to be issued for interest         | 16,364     | 6,459         | _           | -             | 6,459        |
| Shares issued for exploration properties | 525,000    | 210,000       | _           | _             | 210,000      |
| Units issued for cash                    | 1,500,333  | 643,138       | 32,012      | _             | 675,150      |
| Share issuance costs                     | _          | (78,338)      | 17,723      | _             | (60,615)     |
| Share-based compensation                 | _          | _             | 279,244     | _             | 279,244      |
| Loss for the period                      | _          | —             | _           | (550,994)     | (550,994)    |
| Balance at February 29, 2024             | 43,710,405 | \$ 11,535,513 | \$2,005,049 | \$(7,320,640) | \$6,219,923  |

# TOCVAN VENTURES CORP. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited; Expressed in Canadian dollars)

|  | Three months ended |                      |    |                            |
|--|--------------------|----------------------|----|----------------------------|
|  |                    | February 29,<br>2024 |    | February 28,<br>2023       |
| CASH FLOWS USED IN OPERATING ACTIVITIES  |                    |                      |    |                            |
| Net loss   | \$                 | (550,994)            | \$ | (936,731)                  |
| Items not involving cash   |                    |                      |    |                            |
| Interest expense   |                    | 11,164               |    | 13,930                     |
| Share-based compensation   |                    | 279,244              |    | 481,588                    |
| Shares issued for service  |                    | _                    |    | 109,000                    |
| Unrealized loss/(gain) on financial asset  |                    | (221,331)            |    | 47,977                     |
| Realized loss on financial asset   |                    | 533,075              |    | 317,281                    |
| Unrealized gain on convertible debenture   |                    | (612,629)            |    | (394,103)                  |
| Realized loss on convertible debenture   |                    | 693,570              |    | _                          |
| Unrealized gain on warrants payable  |                    | (609,324)            |    | (509,464)                  |
| Changes in non-cash working capital items  |                    |                      |    |                            |
| Receivables  |                    | 160                  |    | (9,852)                    |
| Due to related parties   |                    | (67,838)             |    | (163,054)                  |
| Prepaid expenses   |                    | (1,299)              |    | 184,745                    |
| Accounts payable and accrued liabilities   |                    | (184,972)            |    | 51,344                     |
| Net cash used in operating activities  |                    | (731,174)            |    | (807,339)                  |
| CASH FLOWS FROM FINANCING ACTIVITIES<br>Proceeds from issuance of shares, net<br>Proceeds from warrants exercised<br>Proceeds from options exercised |                    | 614,535              |    | 566,482<br>5,760<br>11,563 |
| Receipts from settlement of equity swaps   |                    | 698,896              |    | 599,313                    |
| Net cash provided by financing activities  |                    | 1,313,431            |    | 1,183,118                  |
| CASH FLOWS USED IN INVESTING ACTIVITIES  |                    |                      |    |                            |
| Exploration and evaluation asset expenditures  |                    | (555,706)            |    | (262,168)                  |
| Net cash used in investing activities  |                    | (555,706)            |    | (262,168)                  |
| Change in cash   |                    | 26,551               |    | 113,611                    |
| Cash, beginning  |                    | 20,825               |    | 86,439                     |
| Cash, ending   | \$                 | 47,376               | \$ | 200,050                    |
| NON-CASH TRANSACTIONS  |                    |                      |    |                            |
| Exploration and evaluation assets included in:   |                    |                      |    |                            |
| Due to related parties   | \$                 | 544,923              | \$ | 216,492                    |
| Accounts payable   | \$                 | 16,908               | \$ | 38,145                     |
| Shares issued for exploration and evaluation assets  | \$                 | 210,000              | \$ | 650,000                    |
| Shares issued for interest payable   | \$                 | 6,459                | \$ | —                          |
| Shares issued on conversion of debenture payable   | \$                 | 1,380,552            | \$ |                            |

# 1. NATURE AND CONTINUANCE OF OPERATIONS

Tocvan Ventures Corp. (the "Company") was incorporated on May 23, 2018, under the Alberta Business Corporations Act. On March 1, 2019, the Company's shares started trading on the Canadian Securities Exchange (the "CSE") under the symbol "TOC".

The Company's head office address is Suite 820 – 1130 West Pender St., Vancouver, British Columbia V6E 4A4 Canada. The registered and records office address is Suite 1150, 707 - 7th Avenue S.W., Calgary, Alberta T2P 3H6 Canada.

On September 15, 2020, the Company incorporated, under the laws of Mexico, a wholly-owned subsidiary, Burgencio S.A. de C.V. ("Burgencio"). Burgencio's office address is Blvd. Morelos No, 639,Col. Bachoco, C.P. 83148, Hermosillo, Sonora, Mexico.

The Company is engaged in the acquisition, exploration and development of mineral properties. At February 29, 2024, the Company had not yet determined whether its properties contain reserves that are economically recoverable. The recoverability of amounts shown for exploration and evaluation assets and related deferred exploration costs is dependent upon the discovery of economically recoverable reserves, confirmation of the Company's interest in the underlying mineral claims, the ability of the Company to obtain necessary financing to complete the development, and upon future profitable production from the exploration and evaluation assets or proceeds from the disposition of the exploration and evaluation asset.

These condensed interim consolidated financial statements have been prepared with the going concern assumption, which assumes that the Company will continue in operation for the foreseeable future and, accordingly will be able to realize its assets and discharge its liabilities in the normal course of operations. At February 29, 2024, the Company had an accumulated deficit of 7,320,640 (August 31, 2023 – 6,769,646) and is expected to incur further losses. The Company will require additional equity financing to continue developing its business and to meet its obligations. While the Company has been successful at raising additional equity financing in the past, there is no guarantee that it will continue to do so in the future, which results in a material uncertainty that casts significant doubt on the Company's ability to continue as a going concern.

The Company's ability to continue its operations and to realize its assets at their carrying values is dependent upon obtaining additional financing and generating revenues sufficient to cover its operating costs. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. These adjustments could be material.

# 2. BASIS OF PREPARATION

# a) Statement of compliance and basis of presentation

## **Basis of Preparation**

These condensed interim consolidated financial statements are prepared in accordance with accounting policies consistent with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretation of the International Financial Reporting Interpretation Committee ("IFRIC").

These condensed interim consolidated financial statements have been prepared on a historical cost basis. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The condensed interim consolidated financial statements of the Company are presented in Canadian dollars unless otherwise indicated, the reporting currency of the Company.

These condensed interim consolidated financial statements were authorized for issue by the Board of Directors on April 29, 2024.

## **Basis of consolidation**

These condensed interim consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, Burgencio. The financial statements of Burgencio are included in the condensed interim consolidated financial statements from the date that control commenced until the date that control ceases. All intercompany transactions and balances have been eliminated. Where necessary, adjustments are made to the financial statements of the subsidiary to bring its accounting policies in-line with those used by the Company.

The functional currency of Burgencio is the Canadian dollar, which is determined to be the currency of the primary economic environment in which Burgencio operates.

#### b) Use of estimates, assumptions and judgments

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed interim consolidated financial statements and the reported amount of expenses during the reporting period. Significant areas requiring the use of management estimates relate to provisions for restoration and environmental obligations and contingent liabilities, share-based compensation, deferred taxes, and the valuation and remeasurement of the financing transactions (Note 4).

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments applying to the Company's condensed interim consolidated financial statements include:

- 1) the classification/allocation of expenses as exploration and evaluation expenditures or operating expenses;
- 2) the determination that the Company will continue as a going concern for the next years;
- 3) the determination whether there have been any events or changes in circumstances that indicate the impairment of its exploration and evaluation assets; and
- 4) classification of financial instruments issued in the financing transactions as liabilities or equity (Note 4).

## 3. EXPLORATION AND EVALUATION ASSETS

#### Title to exploration and evaluation assets

Title to exploration and evaluation ("E&E") asset interests involve certain inherent risks due to the difficulties of determining the validity of certain claims as well as the potential for problems arising from the frequently ambiguous conveyancing history characteristic of many mineral claims. The Company has investigated title to its exploration and evaluation asset and, to the best of its knowledge, title to all of its interests are in good standing. However, this should not be construed as a guarantee of title. The concessions may be subject to prior claims, agreements or transfers and rights of ownership may be affected by undetected defects.

# TOCVAN VENTURES CORP. Notes to the Condensed Interim Consolidated Financial Statements

# For the Three and Six Months Ended February 29, 2024 and February 28, 2023 (Unaudited; Expressed in Canadian Dollars)

#### Summary

| Period ended February 29, 2024      | Pilar        | El Picacho | Total        |
|-------------------------------------|--------------|------------|--------------|
| Acquisition costs                   |              |            |              |
| Balance, August 31, 2023            | \$ 2,640,000 | \$ 196,789 | \$ 2,836,789 |
| Cash                                | 421,088      | 27,128     | 448,216      |
| Shares issued                       | 210,000      | _          | 210,000      |
| Balance, February 29, 2024          | 3,271,088    | 223,917    | 3,495,005    |
| Deferred exploration expenditures   |              |            |              |
| Balance, August 31, 2023            | 2,965,862    | 523,494    | 3,489,356    |
| Geologist fees and assays           | 177,764      | 82,125     | 259,889      |
| Other exploration expenses          | 1,190        | _          | 1,190        |
| Balance, February 29, 2024          | 3,144,816    | 605,619    | 3,750,435    |
| Total E&E assets, February 29, 2024 | \$ 6,415,904 | \$ 829,536 | \$ 7,245,440 |
|                                     |              |            |              |
| Year ended August 31, 2023          | Pilar        | El Picacho | Total        |
| Acquisition costs                   |              |            |              |
| Balance, August 31, 2022            | \$ 1,915,000 | \$ 135,687 | \$ 2,050,687 |
| Cash                                | 75,000       | 61,102     | 136,102      |
| Shares issued                       | 650,000      | _          | 650,000      |
| Balance, August 31, 2023            | 2,640,000    | 196,789    | 2,836,789    |
| Deferred exploration expenditures   |              |            |              |
| Balance, August 31, 2022            | 2,116,564    | 153,177    | 2,269,741    |
| Geologist fees and assays           | 835,480      | 295,628    | 1,131,108    |
| Other exploration expenses          | 13,818       | 74,689     | 88,507       |
| Balance, August 31, 2023            | 2,965,862    | 523,494    | 3,489,356    |
| Total E&E assets, August 31, 2023   | \$ 5,605,862 | \$ 720,283 | \$ 6,326,145 |

## Pilar Project, Sonora, Mexico

On September 22, 2019, the Company signed an option agreement ("Pilar Agreement") to acquire 51% of the Pilar Gold Project in the state of Sonora, Mexico (the "Pilar Project") from Colibri Resource Corp. ("Colibri"). The agreement was amended on August 31, 2021, and the updated conditions are as follows:

|                    | Cash payment     | Exploration work      | Shares             |
|--------------------|------------------|-----------------------|--------------------|
| September 22, 2019 | \$125,000 (paid) | \$Nil                 | 2,000,000 (issued) |
| September 21, 2020 | \$125,000 (paid) | \$175,000 (completed) | 1,000,000 (issued) |
| September 21, 2021 | \$25,000 (paid)  | \$425,000 (completed) | 1,000,000 (issued) |
| September 21, 2022 | \$75,000 (paid)  | \$400,000 (completed) | 1,000,000 (issued) |
| September 21, 2023 | \$75,000 (paid)  | \$500,000 (completed) |                    |
| September 21, 2024 |                  | \$500,000 (completed) |                    |
| TOTAL              | \$425,000        | \$2,000,000           | 5,000,000          |

On September 18, 2023, the Company submitted an exercise notice to Colibri to confirm its 51% ownership of the Pilar gold-silver project as the Company fulfilled its initial commitment under the covenants of the Pilar Agreement.

The Pilar Agreement also gives the Company an option to acquire the remaining 49% interest in the Pilar Project within a six-month period after the Company acquires 51% ownership, or establish a joint venture agreement with Colibri. The option to acquire the additional interest requires a \$2,000,000 cash payment and granting Colibri a 2% net smelter return royalty ("NSR"), 1% of which can be repurchased for an additional cash payment of \$1,000,000.

#### **TOCVAN VENTURES CORP. Notes to the Condensed Interim Consolidated Financial Statements** For the Three and Six Months Ended February 29, 2024 and February 28, 2023 *(Unaudited; Expressed in Canadian Dollars)*

Subsequent to February 29, 2024, the Company has elected to enter into a joint venture with Colibri for the development of the remaining optioned property under the Pilar Agreement. Since the optioned property represents only 4.6% of the total land area controlled and wholly-owned by Tocvan, the management of the Company decided that the funds required to acquire remaining 49% interest in the Pilar Project would be better used for future exploration activities.

During the six months ended February 29, 2024, in accordance with Section 9 (*Anti-Dilution*) of the Pilar Agreement the Company issued to Colibri 525,000 common shares valued at \$210,000.

## Pilar Landholding Expansion

On October 17, 2023, the Company entered into a definitive agreement (the "SV Agreement") with Suaqui Verde Properties ("SVP"), a private owner, for an option to acquire 100% interest in a 2,173 hectare contiguous land immediately adjacent and north of Pilar Project. Under the terms of the SV Agreement, the Company agreed to the following payments:

|   | Cash payment       | <b>Exploration work</b> | Shares    |
|---|--------------------|-------------------------|-----------|
| On closing                              | US\$250,000 (paid) | US\$Nil                 | Nil       |
| Six months after closing <sup>(1)</sup> | US\$200,000        | US\$Nil                 | 250,000   |
| 1 <sup>st</sup> anniversary             | US\$Nil            | US\$100,000             | 500,000   |
| 2 <sup>nd</sup> anniversary             | US\$1,050,000      | US\$150,000             | 500,000   |
| 3 <sup>rd</sup> anniversary             | US\$1,150,000      | US\$250,000             | 750,000   |
| 4 <sup>th</sup> anniversary             | US\$650,000        | US\$250,000             | 250,000   |
| 5 <sup>th</sup> anniversary             | US\$700,000        | US\$250,000             | 250,000   |
| TOTAL                                   | US\$4,000,000      | US\$1,000,000           | 2,500,000 |

<sup>(1)</sup> The Company and SVP reached a verbal agreement to extend the payment deadline until the close of the private placement financing the Company arranged in April of 2024. The Company expects to make the required payment in the first week of May 2024.

SVP will retain a 2% NSR. After the five-year period, the Company can elect to extend the Agreement by another ten years by starting advance royalty payments or purchase full title ownership through additional payment of US\$500,000. The additional acquisition expanded Pilar Project area from 105 hectares to 2,278 hectares.

# El Picacho Project, Sonora, Mexico

On June 7, 2021, the Company signed a letter of commitment to purchase the El Picacho Project ("El Picacho Project") from Recursos Millrock S. de R.L. de C.V. ("Millrock") a Mexican corporation. On signing of the letter of commitment the Company made an initial payment of \$94,196 (US\$78,000).

On September 15, 2021, the Company entered into an assignment agreement with Millrock for an initial five-year option to acquire the El Picacho property from the property owners, Suarez Brothers, within the Caborca Orogenic Gold Belt in Sonora, Mexico. El Picacho consists of 12 mining concessions totaling 2,395 hectares.

To acquire 100% interest in the El Picacho Project, the Company is required to pay Suarez Brothers US\$1,985,600 and an additional payment of US\$60,000 will be required to gain surface rights to use the Picacho Ranch. Both payments are to be paid in a series of instalments ending on April 1, 2026. Millrock is to retain a 2% NSR with the option for the Company to purchase back 1% for US\$1,000,000. Upon full execution of the Option Agreement and completion of all cash payments, an Annual Advance Minimum Royalty ("AAMR") of US\$25,000 will be paid to Millrock, doubling each year until the start of production. AAMR payments will be subtracted from royalty payments on commencement of production.

#### **TOCVAN VENTURES CORP. Notes to the Condensed Interim Consolidated Financial Statements** For the Three and Six Months Ended February 29, 2024 and February 28, 2023 *(Unaudited; Expressed in Canadian Dollars)*

|  | <b>Option payment</b>        | Surface rights payment       |
|--|------------------------------|------------------------------|
| Closing                                      | US\$5,000 (paid by Millrock) | US\$6,000 (paid by Millrock) |
| Six months after closing                     | US\$Nil                      | US\$6,000 (paid)             |
| 1 <sup>st</sup> anniversary                  | US\$21,400 (paid)            | US\$6,000 (paid)             |
| Six months after 1 <sup>st</sup> anniversary | US\$21,400 (paid)            | US\$6,000 (paid)             |
| 2 <sup>nd</sup> anniversary                  | US\$21,400 (paid)            | US\$6,000 (paid)             |
| Six months after 2 <sup>nd</sup> anniversary | US\$21,400 (paid)            | US\$6,000 (paid)             |
| 3 <sup>rd</sup> anniversary                  | US\$250,000                  | US\$6,000 (paid)             |
| Six months after 3 <sup>rd</sup> anniversary | US\$Nil                      | US\$6,000                    |
| 4 <sup>th</sup> anniversary                  | US\$650,000                  | US\$6,000                    |
| Six months after 4 <sup>th</sup> anniversary | US\$Nil                      | US\$6,000                    |
| 5 <sup>th</sup> anniversary                  | US\$1,000,000                | US\$6,000                    |
| TOTAL  | US\$1,990,600                | US\$66,000                   |

A summary of the commitments on El Picacho option agreement and surface rights is as follows:

# 4. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT AND LOSS

The following table summarizes, as at February 29, 2024, and August 31, 2023, the details of the Company's financial assets associated with Sorbie equity swap agreements dated for reference June 28, 2022, and April 5, 2023, measured through profit and loss:

| Financial assets at fair value through profit and loss               | F  | ebruary 29,<br>2024 | August 31,<br>2023 |
|--|----|---------------------|--------------------|
| Balance at the beginning of the period                               | \$ | 1,355,240           | \$ 2,252,532       |
| Addition of financial assets (initial recognition)                   |    | _                   | 604,357            |
| Cash received during the period                                      |    | (698,896)           | (1,391,822)        |
| Change in cash receivable subsequent to the period-end               |    | 30,062              | (15,632)           |
| Realized loss on the Sorbie settlements                              |    | (533,075)           | (596,583)          |
| Unrealized gain on revaluation of the financial assets to fair value |    | 221,331             | 502,388            |
| Balance at the end of the period                                     | \$ | 374,662             | \$ 1,355,240       |

## June 28, 2022, Equity Swap Agreement with Sorbie Bornholm LP

#### Background

On June 28, 2022, the Company entered into a financing transaction with Sorbie Bornholm LP ("Sorbie") whereby the Company agreed to issue 3,200,000 units (the "Sorbie Unit") and 2,809 convertible notes with a face value of \$1,000 per note (the "Sorbie Notes") in exchange for 24 monthly cash payments (the "Monthly Settlements") that were measured against a benchmark price of \$1.10 per share (the "Benchmark") with a set number of shares totaling \$5,125,000 at Benchmark (the "Sorbie Transaction") (Note 9).

The actual Monthly Settlements are determined based on a volume weighted average share price ("VWAP") for 20 trading days prior to the Monthly Settlements. If the measured share price exceeds the Benchmark for the Monthly Settlements, the Company will receive more than 100% of the expected Monthly Settlements. However, should the share price be below the Benchmark, the Company will receive less than 100% of the Monthly Settlements.

Each Sorbie Unit consists of one common share and one warrant entitling Sorbie to purchase one additional common share at a price of \$1.20 until June 28, 2025. The Sorbie Notes mature on June 28, 2025, can be converted, at discretion of the note holder, into 1,220 common shares per Sorbie Note. The Sorbie Notes pay non-compounding interest at 1% per year, which is payable annually in common shares. In connection with the Sorbie

(Unaudited; Expressed in Canadian Dollars)

Notes, the Company issued 1,713,490 detachable warrants that entitle Sorbie to purchase up to 1,713,490 additional common shares at a price of \$1.30 per share until June 28, 2025, and an additional 1,713,490 detachable warrants that entitle Sorbie to purchase up to an additional 1,713,490 common shares at a price of \$1.40 per share until June 28, 2025.

To determine the fair value of the Monthly Settlements the Company uses a Monte Carlo simulation.

Based on the terms of the Monthly Settlements, the Company calculated the expected future VWAP share price at each Monthly Settlement, multiplied by the number of predetermined shares per the payment schedule and then discounted using the risk-free rate to determine the present value of the future cash flows.

As at February 29, 2024, and August 31, 2023, the fair value of expected cash flows was calculated using the following assumptions:

| As at  | February 29,<br>2024 | August 31,<br>2023 |
|--|----------------------|--------------------|
| Benchmark price                                      | \$1.10               | \$1.10             |
| Total number of remaining Settlements <sup>(1)</sup> | 4                    | 10                 |
| Share price on the valuation date                    | \$0.375              | \$0.57             |
| Volatility   | 62.31%               | 75%                |
| Risk-free rate                                       | 4.18%                | 5.13%              |
| Fair value of expected cash flows                    | \$322,422            | \$1,040,585        |

<sup>(1)</sup> The Monthly Settlements were valued based on 182,806 shares, with the final Monthly Settlement valued based on 182,804 shares.

To determine the allocation of the fair value of the Monthly Settlements, the Company analyzed Sorbie Units and Sorbie Notes under guidance available under IFRS 9 *Financial Instruments*. IFRS requires that the terms of a convertible instrument are analyzed, and each component separately accounted for according to the definitions of financial liability and equity. The Company determined that Sorbie Notes and the warrants that were issued as part of the Sorbie Notes and Sorbie Units were liability, therefore the fair values of future Monthly Settlements were allocated first to the Sorbie Notes, then to the warrants with the remaining value allocated to the shares issued as part of the Sorbie Units.

As at February 29, 2024, and August 31, 2023, Sorbie Notes, Warrants, and Shares issued as part of Sorbie Units were valued as follows:

|  | February 29,<br>2024 | August 31,<br>2023 |
|--|----------------------|--------------------|
| Sorbie Notes   | \$ 663,398           | \$ 1,958,304       |
| Warrants to acquire up to 1,713,490 Shares at \$1.30 per Share | 27,996               | 155,929            |
| Warrants to acquire up to 1,713,490 Shares at \$1.40 per Share | 23,531               | 140,511            |
| Warrants to acquire up to 3,200,000 Shares at \$1.20 per Share | 62,624               | 324,350            |
| 3,200,000 Shares issued as part of the Sorbie Units            | _                    | _                  |
| Total  | \$ 777,549           | \$ 2,579,094       |

## Exercised Sorbie Notes

During the six-month period ended February 29, 2024, the Company issued 1,683,600 common shares at \$0.82 per share on conversion of 1,380 Sorbie Notes and issued 16,364 common shares for accrued interest payable of \$6,459 at an average price of \$0.39 per share. The conversion of Sorbie notes resulted in realized loss of \$693,570 (2023 - \$Nil).

Sorbie Notes were determined to be current liability as they may be settled into shares of the Company at the election of Sorbie at any time. Sorbie Notes are revalued at each reporting date based on the fair market value of the Company's shares on reporting date. During the six months ended February 29, 2024, the Company recorded an unrealized gain of \$612,629 (2023 – \$394,103) on revaluation on the remaining Sorbie Notes.

#### Sorbie Warrants

As at February 29, 2024, the warrants issued as part of the Sorbie Transaction had a fair value of \$114,151 (2023 – \$620,790) and were valued based on the Black Scholes Option Pricing Model using the following assumptions:

|                                   | February 29,    | August 31,      |
|-----------------------------------|-----------------|-----------------|
|                                   | 2024            | 2023            |
| Share price on the valuation date | \$0.375         | \$0.57          |
| Exercise price                    | \$1.20 - \$1.40 | \$1.20 - \$1.40 |
| Years to exercise                 | 1.33            | 1.83            |
| Risk free rate                    | 4.18%           | 4.73%           |
| Volatility                        | 70.22%          | 70.00%          |

On February 29, 2024, the Company recognized \$506,639 in unrealized gain (2023 – \$509,464) on revaluation of the Sorbie warrants to their fair market value.

#### Monthly Settlements

As at February 29, 2024, the Company has recorded a total of \$485,627 (2023 – \$584,488) representing six Monthly Settlements, of which \$507,454 was received during the period ended February 29, 2024, including receivable recorded in the previous period of \$94,639. The February Monthly Settlement of \$72,812 was recorded as receivable as it was received subsequent to February 29, 2024. The difference between each Monthly Settlement's fair value as at the initial recognition on June 28, 2022, and the actual Monthly Settlement received is recorded through profit and loss as realized gain or loss for the period. For the period ended February 29, 2024, the Company recorded a realized loss on settlement of \$414,187 (2023 – \$317,281).

At February 29, 2024, the fair value of the remaining four Monthly Settlements was determined to be \$322,422 (2023 – \$1,040,585). The difference between the initial valuation of the Monthly Settlements and their value as at the reporting date is recorded in the profit and loss statement as unrealized gain or loss on the financial asset. As at February 29, 2024, the Company recognized \$181,650 as unrealized loss (2023 – \$47,977) on the financial asset.

## April 5, 2023, Equity Swap Agreement with Sorbie Bornholm LP

## Background

On April 5, 2023, Tocvan entered into a financing transaction (the "April Sorbie Transaction") with Sorbie whereby the Company agreed to issue 1,102,941 units (the "April Sorbie Units") for a total consideration of \$600,000. The units consisted of one common share priced at \$0.544 and one-half share purchase warrant entitling the holder to purchase one additional common share at a price of \$0.68 until April 5, 2026. In addition, the Company settled the financing fee of \$36,000 by issuing 66,177 common shares and 33,088 share purchase warrants on the same terms as April Sorbie Units. A total of 1,169,118 common shares and 584,559 share purchase warrants were issued to Sorbie for the financing arrangement entered on April 5, 2023.

#### **TOCVAN VENTURES CORP. Notes to the Condensed Interim Consolidated Financial Statements** For the Three and Six Months Ended February 29, 2024 and February 28, 2023 *(Unaudited; Expressed in Canadian Dollars)*

Furthermore, on April 5, 2023, the Company entered into an equity swap arrangement under a Sharing Agreement with Sorbie to allow settlement provisions for \$600,000 to be paid out in 12 monthly tranches of \$50,000 with equivalent number of settlement shares at 68,965 per month totaling 827,586 shares (the 12<sup>th</sup> month number of shares to be at 68,971). The monthly amounts to be paid out depend on how the Company's share price varies against a benchmark price (the "April Benchmark") set at \$0.725. The monthly share price is calculated by using the VWAP of the Company's share price within 20-trading days prior to settlement date multiplied by the number of settlement shares. If the VWAP of the Company's price is less than the April Benchmark price, the Company will receive less than 100% of the monthly cash settlement, if the VWAP of the Company's share price is more than the April Benchmark price, the Company will receive more than 100% of the monthly cash settlement. The number of settlement shares will not fluctuate and will remain constant at each settlement date.

To determine the fair value of the April Sorbie Settlements the Company uses Monte Carlo Simulation.

Based on the terms of the April Sorbie Settlements, the Company calculated the expected future VWAP of the Company's share price at each April Sorbie Settlement date, multiplied by the number of predetermined shares per the payment schedule and then discounted using the risk-free rate to determine the present value of the future cash flows.

At February 29, 2024, and August 31, 2023, the fair value of expected cash flows was calculated using the following assumptions:

| As at   | February 29,<br>2024 | August 31,<br>2023 |
|---|----------------------|--------------------|
| April Benchmark   | \$0.725              | \$0.725            |
| Total number of remaining April Sorbie Settlements <sup>(1)</sup> | 2                    | 8                  |
| Share price on the valuation date                                 | \$0.375              | \$0.57             |
| Volatility  | 82.51%               | 70.00%             |
| Risk-free rate  | 4.18%                | 5.12%              |
| Fair value of expected cash flows                                 | \$52,240             | \$314,655          |

(1) The fair value of expected cash flows was valued based on April Sorbie Settlements of 68,965 shares, with the final April Sorbie Settlement valued based on 68,971 shares.

To determine the allocation of the fair value of the April Sorbie Settlements, the Company analyzed April Sorbie Units under guidance available under IFRS 9 *Financial Instruments and* IAS 32. The Company determined that April Sorbie Warrants were liability, therefore the fair values of future Monthly Settlements were allocated first to the April Sorbie Warrants with the remaining value allocated to the shares issued as part of the April Sorbie Units.

#### April Sorbie Warrants

At February 29, 2024, and August 31, 2023, the Warrants and Shares issued as part of April Sorbie Units were valued as follows:

|  | Fe | bruary 29,<br>2024 | L  | August 31,<br>2023 |
|--|----|--------------------|----|--------------------|
| Warrants to acquire up to 584,559 Shares at \$0.68 per Share | \$ | 53,960             | \$ | 156,645            |
| Equity   |    | 348,079            |    | 348,079            |
| Total  | \$ | 402,039            | \$ | 504,724            |

(Unaudited; Expressed in Canadian Dollars)

At February 29, 2024, the warrants issued as part of the April Sorbie Transaction were valued at \$53,960 (2023 - \$156,645) based on the Black Scholes Option Pricing Model using the following assumptions:

|                                   | February 29,<br>2024 | August 31,<br>2023 |
|-----------------------------------|----------------------|--------------------|
| Share price on the valuation date | \$0.375              | \$0.57             |
| Exercise price                    | \$0.68               | \$0.68             |
| Years to exercise                 | 2.10                 | 2.60               |
| Risk-free rate                    | 4.18%                | 4.68%              |
| Volatility                        | 70.74%               | 80.73%             |

At February 29, 2024, the Company recognized an unrealized gain of \$102,685 (2023 – \$Nil) on revaluation of the April Sorbie Warrants to their fair market value.

During the six-month period ended February 29, 2024, the Company received a total of \$191,442 in April Sorbie Settlements, which included \$35,703 recorded as receivable at August 31, 2023 (2023 – \$Nil). A further Apil Sorbie Settlement of \$27,469 was recorded as receivable as the funds were received subsequent to February 29, 2024.

The difference between April Sorbie Settlement's fair value as at the initial recognition on April 5, 2023, and the actual cash received is recorded through profit and loss as realized income or loss for the period. For the six-month period ended February 29, 2024, the Company recorded a realized loss on settlement of \$118,888 (2023 – \$Nil).

At February 29, 2024, the fair value of the future April Sorbie Settlements was determined to be \$52,240. The difference between the initial valuation of the April Sorbie Settlements and their value at the reporting date is recorded in the profit and loss statement as unrealized gain or loss for the period. As at February 29, 2024, the Company recognized \$39,681 (2023 – \$Nil) as unrealized loss on the financial asset.

## Sensitivity Analysis

The following table illustrates the impact of a 10% increase and a 10% decrease in the Company's share price on the fair value of the financial assets and financial liabilities from Sorbie transactions:

|                          | Fair Ma                  | arket Value       | 10%      |                       |    | 10%      |
|--------------------------|--------------------------|-------------------|----------|-----------------------|----|----------|
|                          |                          | As at Share Price |          | Share Pric<br>Decreas |    |          |
| Transactions             | <b>February 29, 2024</b> |                   | Increase |                       |    |          |
| Monthly Settlements      | \$                       | 322,422           | \$       | 323,639               | \$ | 321,446  |
| April Sorbie Settlements |                          | 52,240            |          | 56,974                |    | 46,940   |
| Warrants @\$1.20         |                          | (62,624)          |          | (84,582)              |    | (44,376) |
| Warrants @\$1.30         |                          | (27,996)          |          | (38,146)              |    | (19,643) |
| Warrants @\$1.40         |                          | (23,531)          |          | (32,327)              |    | (16,358) |
| Warrants @\$0.68         |                          | (53,960)          |          | (65,476)              |    | (43,298) |
|                          | \$                       | 206,551           | \$       | 160,082               | \$ | 244,711  |

# 5. RECEIVABLES

|                                       | February 29,<br>2024 | August 31,<br>2023 |
|---------------------------------------|----------------------|--------------------|
| Sorbie Monthly Settlements receivable | \$ 100,281           | \$ 130,343         |
| GST receivable                        | 4,357                | 4,516              |
|                                       | \$ 104,638           | \$ 134,859         |

#### 6. **PREPAID EXPENSES**

|                                   | February 29,<br>2024 |       | ugust 31,<br>2023 |
|-----------------------------------|----------------------|-------|-------------------|
| Advertising and promotion         | \$ 57,067            | \$    | 42,131            |
| Deferred exploration expenditures | 1,296                | -<br> | 4,265             |
| Regulatory fees                   | 6,773                |       | 17,437            |
| Miscellaneous                     | 350                  | )     | 354               |
|                                   | \$ 65,486            | \$    | 64,187            |

## 7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

|                     | February 29,<br>2024 | August 31,<br>2023 |
|---------------------|----------------------|--------------------|
| Accounts payable    | \$ 104,727           | \$ 287,167         |
| Accrued liabilities | 88,750               | 79,137             |
|                     | \$193,477            | \$ 366,304         |

## 8. SHARE CAPITAL

#### Authorized and issued

The authorized share capital consists of an unlimited number of common shares without par value (the "Common Shares") and an unlimited number of shares designated as preferred shares. At February 29, 2024, the Company had 43,710,405 common shares (2023 – 39,985,108) and no preferred shares issued and outstanding.

## Shares issued during the period ended February 29, 2024

On November 1, 2023, the Company issued 854,000 common shares for a total consideration of \$700,280 to Sorbie pursuant to the exercise of 700 Sorbie Notes with each note convertible into 1,220 common shares (Note 9). The total interest of \$2,397 accrued on the 700 Sorbie Notes up to November 1, 2023, was converted into 5,387 common shares, which were issued on December 12, 2023.

On November 28, 2023, the Company closed the first tranche of a non-brokered private placement issuing 820,000 units at \$0.45 per unit for gross proceeds of \$369,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of \$0.60 exercisable within 24 months from the closing of the first tranche, subject to accelerated expiry provisions. The warrants were valued at \$8,200.

In connection with the private placement, the Company paid a total of \$32,399 in cash finders' fees, \$7,500 in legal fees, and issued 72,000 finders' warrants. Each finders' warrant entitles the holder to acquire one additional common share at a price of \$0.44 exercisable within 24 months from the closing of the first tranche. The finders' warrants were valued at \$12,360 using Black Scholes Option Pricing Model with the following assumptions:

| Share price    | \$0.44    |
|----------------|-----------|
| Exercise price | \$0.45    |
| Exercise term  | 24 months |
| Risk free rate | 4.29%     |
| Volatility     | 68.26%    |

On December 11, 2023, the Company closed the second and final tranche of the non-brokered private placement issuing 680,333 units for a gross proceeds of \$306,150 at \$0.45 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common

(Unaudited; Expressed in Canadian Dollars)

share at a price of \$0.60 exercisable within 24 months from the closing date, subject to accelerated expiry provisions. The warrants were valued at \$23,812.

In relation to the second tranche of the private placement, the Company paid \$5,550 in legal fees and \$15,165 in finders' fees; in addition, the Company issued 33,700 finders' warrants. Each finders' warrant entitles the holder to acquire one additional common share at a price of \$0.45 exercisable within 24 months from the closing of the second tranche. The finders' warrants were valued at \$5,363 using Black Scholes Option Pricing Model with the following assumptions:

| Share price    | \$0.415   |
|----------------|-----------|
| Exercise price | \$0.45    |
| Exercise term  | 24 months |
| Risk free rate | 4.18%     |
| Volatility     | 70.66%    |

On December 19, 2023, the Company issued 525,000 common shares valued at \$210,000 to Colibri in accordance with Section 9 (*Anti-Dilution Clause*) of Pilar Agreement.

On February 2, 2024, the Company issued 826,600 common shares valued at \$680,272 to Sorbie upon exercise of 680 Sorbie Notes and an additional 10,977 common shares to settle accrued interest on the exercised Sorbie Notes of \$4,061.

#### Shares issued during the year ended August 31, 2023

On September 21, 2022, the Company issued 1,000,000 Common Shares with a fair value of \$650,000 as payment for Pilar Project pursuant to the Property Option Agreement dated September 22, 2019, as amended on August 31, 2021, between the Company and Colibri (Note 3).

On September 27, 2022, the Company issued 9,600 Common Shares on exercise of finder's warrants with an exercise price of \$0.60 for total gross proceeds of \$5,760. On December 2, 2022, the Company issued 18,750 Common Shares on exercise of options at an exercise price of \$0.35 for total gross proceeds of \$6,563. The share price at the time the options were exercised was \$0.47.

On January 6, 2023, the Company issued 12,500 Common Shares on exercise of options at an exercise price of \$0.40 for total proceeds of \$5,000. The share price at the time the options were exercised was \$0.55.

On February 16, 2023, the Company closed a non-brokered private placement (the "Offering") by issuing a total of 1,227,353 units of its common stock at a price of \$0.52 per unit for gross proceeds of \$638,224. The private placement consisted of three tranches, which closed on January 30, 2023, February 9, 2023, and February 16, 2023. Each unit consisted of one Common Share and one-half of one Common Share purchase warrant (the "Warrant"). Each full Warrant entitles the holder to acquire additional Common Share at a price of \$0.62 exercisable within 18 months from the close of the respective tranche. In connection with the Offering, the Company paid \$15,400 in legal fees and \$56,342 in cash commissions. In addition, the Company issued 108,351 finders warrants ("Finders' Warrants") entitling the holder to acquire one Common Share at a price of \$0.52 exercisable within 18 months from the close of the respective tranche. The Finders' Warrants were valued at \$26,517 using Black Scholes option pricing model with the following assumptions:

| Share price<br>Exercise price | \$0.52 - \$0.60<br>\$0.52 |
|-------------------------------|---------------------------|
| Exercise term                 | 18 months                 |
| Risk free rate                | 3.9%                      |
| Volatility                    | 79.16%-80.10%             |

(Unaudited; Expressed in Canadian Dollars)

On February 22, 2023, the Company issued 218,000 Common Shares at \$0.50 per share for a total value of \$109,000 to a vendor for services rendered in production and broadcasting media in accordance with the agreement dated August 15, 2022.

On April 5, 2023, the Company completed a financing transaction with Sorbie (Note 4). As part of the April Sorbie transaction, the Company issued a total of 1,169,118 April Sorbie Units . Each April Sorbie Unit consisted of one common share and one-half of one common share purchase warrant ("April Sorbie Warrant"). Each full April Sorbie Warrant entitles Sorbie to acquire one additional share at an exercise price of \$0.68 exercisable until April 5, 2026. The Company allocated the fair value of the future April Sorbie Settlements expected to be received from the April Sorbie Transaction between all the components of the April Sorbie Transaction based on the guidance available under IAS 32. Based on this, on initial recognition of its fair value at \$604,357, the Company allocated \$256,278 to the April Sorbie Warrants with \$348,079 allocated to the shares issued as part of the April Sorbie Transaction. In connection with April Sorbie Transaction, the Company paid cash of \$13,000 in legal fees, which were recorded as share issuance cost.

On July 18, 2023, the Company settled accrued interest of \$28,090 on Sorbie Notes by issuing 59,137 common shares. The Sorbie Notes carry a non-compounding interest of 1% per annum to be settled annually in cash or common shares at Sorbie's discretion (Notes 4 and 9).

## **Stock Options**

The Company has a rolling stock option plan under which it is authorized to grant options to directors, employees and consultants, to acquire up to 10% of the issued and outstanding shares. The exercise price of each option is based on the market price of the Company's stock at the date of grant. The options can be granted for a maximum term of five years and vest as determined by the board of directors.

|                                  | Six months ended<br>February 29, 2024 |  |      | A                             | Year en<br>ugust 31 |  |
|----------------------------------|---------------------------------------|--|------|-------------------------------|---------------------|--|
|                                  | Number<br>of Stock<br>Options         | Weighted<br>Average<br>Exercise<br>Price |      | Number<br>of Stock<br>Options | A                   | Veighted<br>Average<br>Exercise<br>Price |
| Options outstanding, beginning   | 2,662,500                             | \$                                       | 0.60 | 2,725,250                     | \$                  | 0.54                                     |
| Options exercised                | _                                     |  | n/a  | (31,250)                      | \$                  | 0.37                                     |
| Options expired                  | _                                     |  | n/a  | (431,500)                     | \$                  | 0.27                                     |
| Options granted                  | 500,000                               | \$                                       | 0 50 | 400,000                       | \$                  | 0.72                                     |
| Options outstanding, ending      | 3,162,500                             | \$                                       | 0.59 | 2,662,500                     | \$                  | 0.60                                     |
| Options outstanding, exercisable | 3,062,500                             | \$                                       | 0.59 | 2,362,500                     | \$                  | 0.59                                     |

As at February 29, 2024, the following incentive stock options are outstanding:

| Number of Stock<br>Options | Exercise<br>Price | Years<br>remaining | Expiry Date        | Exercisable at<br>February 29,<br>2024 |
|----------------------------|-------------------|--------------------|--------------------|--|
| 150,000                    | \$ 0.15           | 0.65               | October 24, 2024   | 150,000                                |
| 181,250                    | \$ 0.35           | 1.53               | September 11,2025  | 181,250                                |
| 281,250                    | \$ 0.40           | 1.56               | September 21, 2025 | 281,250                                |
| 100,000                    | \$ 0.40           | 1.79               | December 15, 2025  | 100,000                                |
| 150,000                    | \$ 0.35           | 1.89               | January 19, 2026   | 150,000                                |
| 200,000                    | \$ 0.80           | 2.18               | May 3, 2026        | 200,000                                |
| 1,200,000                  | \$ 0.72           | 3.43               | August 5, 2027     | 1,200,000                              |
| 400,000                    | \$ 0.72           | 4.14               | April 20, 2028     | 300,000                                |
| 500,000                    | \$ 0.50           | 4.60               | October 3, 2028    | 500,000                                |
| 3,162,500                  | \$ 0.59           | 3.10               |                    | 3,062,500                              |

As at February 29, 2024, the weighted average life of the options was 3.10 years.

#### Share-based compensation

On October 3, 2023, the Company granted options to acquire up to 500,000 shares to certain consultants. The options entitle the holders to purchase one Common Share for each option held at a price of \$0.50 per Common Share expiring on October 3, 2028. The options vested at the time of grant. In connection with this grant, the Company calculated the fair value of the share-based compensation to be \$205,984 using the Black Scholes Option Pricing Model with the following assumptions: share price - \$0.55; exercise price - \$0.50; expected life -5 years; expected volatility - 93.50%; risk free interest rate - 4.48%.

During the six-month period ended February 29, 2024, the Company recognized \$279,244 (2023 - \$481,588) in share-based compensation.

## Warrants

|                                 |                       | Six months ended<br>February 29, 2024 | Year ended<br>August 31, 2023 |                                    |
|---------------------------------|-----------------------|---------------------------------------|-------------------------------|------------------------------------|
|                                 | Number of<br>Warrants | Weighted Average<br>Exercise Price    | Number of<br>Warrants         | Weighted Average<br>Exercise Price |
| Warrants outstanding, beginning | 9,546,755             | \$1.21                                | 9,491,103                     | \$ 1.22                            |
| Warrants issued                 | 1,606,033             | \$0.59                                | 1,306,587                     | \$ 1.21                            |
| Warrants exercised              | _                     | n/a                                   | (9,600)                       | \$ 0.60                            |
| Warrants expired                | (890,158)             | \$1.37                                | (1,241,335)                   | \$ 0.60                            |
| Warrants outstanding, ending    | 10,262,630            | \$1.11                                | 9,546,755                     | \$ 1.21                            |

At February 29, 2024, the following subscribers' warrants are outstanding:

|                   | Number of    | Weighted              |
|-------------------|--------------|-----------------------|
| Expiry Date       | Subscribers' | Average               |
|                   | Warrants     | <b>Exercise Price</b> |
| May 9, 2024       | 432,750      | \$ 1.40               |
| June 14, 2024     | 243,500      | \$ 1.40               |
| June 28, 2025     | 1,713,490    | \$ 1.30               |
| June 28, 2025     | 1,713,490    | \$ 1.40               |
| June 28, 2025     | 3,200,000    | \$ 1.20               |
| July 30, 2024     | 220,856      | \$ 0.62               |
| August 9, 2024    | 267,335      | \$ 0.62               |
| August 16, 2024   | 125,486      | \$ 0.62               |
| April 5, 2026     | 584,559      | \$ 0.68               |
| November 28, 2025 | 820,000      | \$ 0.60               |
| December 11, 2025 | 680,333      | \$0.60                |
|                   | 10,001,799   | \$ 1.11               |

At February 29, 2024, the weighted average life of the subscribers' warrants was 1.31 years.

(Unaudited; Expressed in Canadian Dollars)

At February 29, 2024, the following finders' warrants are outstanding:

| Expiry Date       | Number of<br>Finders'<br>Warrants | Weighted<br>Average<br>Exercise Price |
|-------------------|-----------------------------------|---------------------------------------|
| May 9, 2024       | 34.620                            | \$ 0.80                               |
| June 14, 2024     | 12,160                            | \$ 0.82                               |
| July 30, 2024     | 39,787                            | \$ 0.52                               |
| August 9, 2024    | 43,467                            | \$ 0.52                               |
| August 16, 2024   | 25,097                            | \$ 0.52                               |
| November 28, 2025 | 72,000                            | \$ 0.45                               |
| December 11, 2025 | 33,700                            | \$0.45                                |
|                   | 260,831                           | \$ 0.54                               |

At February 29, 2024, the weighted average life of the finders' warrants was 0.93 years.

# 9. CONVERTIBLE NOTES

In connection with the Sorbie Transaction (Note 4), the Company issued a total of 2,809 convertible notes with a face value of \$1,000 per Sorbie Note for a total of \$2,810,124 maturing on June 28, 2025. Each Sorbie Note has a coupon rate of 1% per annum, non-compounding, and is payable in common shares. Each note is convertible into 1,220 common shares. The Sorbie Notes can be converted to shares at discretion of Sorbie, provided that notice in writing setting out the number of Sorbie Notes to be converted and the proposed date for conversion is given to the Company at least five business days prior to the proposed date for conversion. In addition, the Sorbie Notes cannot be redeemed prior to the maturity date, when they automatically convert to Common Shares of the Company.

The Company determined that, since the consideration receivable for Sorbie Notes cannot be readily determined, and due to convertibility of the Sorbie Notes at the discretion of Sorbie at any time after the close of the Sorbie Transaction and before their maturity date, the fair value of these notes should be recorded as current liability with any changes in the fair value being recognized as profit or loss.

During the six months ended February 29, 2024, the Company issued a total of 1,699,964 common shares on conversion of 1,380 Sorbie Notes and \$6,459 in interest accrued thereon up to the date of exercise. The Company recorded a realized loss of \$693,570 on conversion (2023 - \$Nil).

At February 29, 2024, the Company recognized unrealized gain of 612,629 (2023 – 394,103) on revaluation of the remaining Sorbie Notes, which resulted from the decrease of the Company's share price from 0.57 at August 31, 2023, to 0.375 on February 29, 2024.

At February 29, 2024, the Company had 9,631 (2023 - 18,855) in interest accrued and payable on Sorbie Notes. During the six-month period ended February 29, 2024, the Company recognized 11,164 (2023 - 13,930) in interest expense relating to the Sorbie Notes.

# 10. RELATED PARTY TRANSACTIONS

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers. The remuneration of directors and key management personnel during the six-month periods ended February 29, 2024 and February 28, 2023 was as follows:

| Description                       | February 29,<br>2024 | February 28,<br>2023 |
|-----------------------------------|----------------------|----------------------|
| Consulting fees                   | \$ 6,000             | \$ -                 |
| Deferred exploration expenditures | 157,904              | 292,937              |
| Management fees                   | 24,000               | 30,000               |
| Share-based compensation          | 36,630               | 222,272              |
|                                   | \$ 224,534           | \$ 545,209           |

## **Related party balances**

At February 29, 2024, \$26,000 (2023 – \$46,143) was owed to the Company's CEO and a company controlled by the CEO including \$21,052 owed for reimbursable expenditures covering office and miscellaneous travelrelated expenses. During the six-month period ended February 29, 2024, the Company incurred \$24,000 in management fees to the CEO (2023 - \$24,000), and \$6,000 in deferred exploration expenditures with a company controlled by the CEO (2023 - \$6,000).

At February 29, 2024, \$566,693 was owed to a company controlled by a director of the Company (2023 – \$462,143). During the six-month period ended February 29, 2024, the Company incurred \$151,904 in deferred exploration expenditures with the company controlled by the director of the Company (2023 – \$286,937).

At February 29, 2024, Nil (2023 - Nil) was owed to the CFO of the Company. During the six-month period ended February 29, 2024, the Company incurred \$6,000 in consulting fees to the CFO (2023 - \$6,000, which were recorded as part of management fees).

At August 31, 2023, the Company owed its former CEO and director \$3,150 for services, these fees were paid during the six-month period ended February 29, 2024. In addition, \$7,650 was owed to a company controlled by the former CEO and director. This amount has been reclassified to accounts payable and accrued liabilities as at February 29, 2024.

All amounts due to related parties are unsecured, non-interest bearing, and with no fixed repayment terms.

# 11. CAPITAL MANAGEMENT

The Company considers its capital to consist of shareholders' equity. The Company's objective when managing capital is to maintain adequate levels of funding to support the development of its businesses and maintain the necessary corporate and administrative functions to facilitate these activities. This is done primarily through debt and equity financing. Future financings are dependent on market conditions and there can be no assurance the Company will be able to raise funds in the future. There were no changes to the Company's approach to capital management during the year. The Company is not subject to externally imposed capital requirements.

## 12. FINANCIAL INSTRUMENTS

#### a. Fair Value

The Company's financial instruments consist of cash, amounts receivable, marketable securities, accounts payable, accrued liabilities and due to related parties classified at amortized cost. The fair values of these financial instruments approximate their carrying values because of their current nature. The financial asset, debenture payable, and warrants payable are all classified at FVTPL. Financial assets and liabilities at fair value through profit and loss are revalued at each reporting date based on the three levels of a fair value hierarchy.

The following table summarizes the carrying values of the Company's financial instruments:

|  | February 29,<br>2024 | August 31,<br>2023 |
|--|----------------------|--------------------|
| Financial assets at amortized cost (i)                           | \$ 152,014           | \$ 155,684         |
| Financial assets at fair value through profit and loss (ii)      | \$ 374,662           | \$ 1,355,240       |
| Financial liabilities at amortized cost (iii)                    | \$ 786,170           | \$ 885,390         |
| Financial liabilities at fair value through profit and loss (iv) | \$ 831,509           | \$ 2,735,739       |

*(i) Cash and amounts receivable* 

(ii) Monthly Settlements resulting from Sorbie Transactions (Note 4)

(iii) Due to related parties, accounts payable and accrued liabilities

(iv) Sorbie Notes and warrants payable issued to Sorbie as a result of Sorbie Transactions (Notes 4, 8 and 9)

#### b. Credit Risk

Credit risk is the risk of loss associated with the counterparty's inability to fulfill its payment obligations. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, which is held with a high credit quality financial institution, Monthly Settlements receivable as a result of Sorbie Transactions, and to a smaller extent GST receivable from the Government of Canada.

## c. Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined above.

The Company monitors its ability to meet its short-term exploration and operating expenditures by raising additional funds through share issuances when required. The Sorbie Notes mature on June 28, 2025 (Notes 4 and 9) however, Sorbie may convert to shares at any time. The warrants payable can only be settled in shares. The Company's other financial liabilities have contractual maturities of 30 days or are due on demand and are subject to normal trade terms.

#### d. Foreign Exchange Risk

Foreign exchange risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company has financial risk arising from fluctuations in foreign exchange rates as the Company, through its wholly owned subsidiary, does own foreign currency denominated financial assets and liabilities.

#### e. Interest Rate Risk

Interest rate risk is the risk that arises from fluctuating interest rates. The Company is not exposed to significant interest rate risk.

#### f. Price risk

The Company is exposed to price risk with respect to commodity prices. Commodity price risk is defined as the potential adverse impact on earnings and economic value due to commodity price movements and volatilities. The Company closely monitors the commodity prices of precious metals and the stock market to determine the appropriate course of action to be taken by the Company. The Company is exposed to equity price risk since Sorbie Monthly Settlements are affected by the movement of the Company's share price.

# **13.** SUBSEQUENT EVENTS

On April 24, 2024, the Company closed the first tranche of a non-brokered private placement (the "April Financing") issuing 5,999,514 units at a price of \$0.35 per unit (the "April Unit") for gross proceeds of \$2,099,830. Each unit consists of one common share and one share purchase warrant exercisable at \$0.50 per common share for a period of 36 months from the closing date. The Company paid \$52,885 in finders' fees and issued 151,100 finders' warrants at an exercise price of \$0.35 expiring April 25, 2027.

Included in the April Financing, were 4,285,714 units issued to Sorbie in exchange for \$1,500,000, which were deposited with a third-party escrow agent and will be delivered in monthly tranches of \$62,500 over the 24-month period pursuant to the terms and conditions of a sharing agreement between the Company and Sorbie dated June 28, 2022, as amended on April 5, 2023, and further amended on April 24, 2024. The monthly payouts will be measured against a benchmark price of \$0.48 per share. In addition, Sorbie received an additional 300,000 units on the same terms as April Units in lieu of a \$105,000 corporate finance fee in accordance with the agreements signed with Sorbie on April 24, 2024.